KYMR
NASDAQ
$111.06
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $125.14 (+12.68%)
Market Cap
$9.38B
Free Cash Flow Yield
-2.60%
Beta (5Y)
1.52
Price Chart
Valuation
Market Cap$9.38B
P/S182.36
P/B5.99
Profitability
Total Revenue (TTM)$51M
Gross Profit (TTM)-$283M
EBITDA-$351M
Operating Margin-244.9%
EPS-$4.14
Financial Health
Free Cash Flow Yield-2.60%
Growth & Risk
Revenue 5Y CAGR+0.86%
Beta (5Y)1.52
Sharpe Ratio1.60